je.st
news
Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play
2016-03-02 23:40:43| Biotech - Topix.net
I first bought and wrote about Portola Pharmaceuticals in mid-2014, when the stock was revisiting its brief peak around $30 that it first hit in September 2013. It had IPO'ed in May at $15, so Friday's closing price of $27.79 still represents a successful IPO.
Tags: business
play
reports
analysis
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||